Nav: Home

UCLA study overturns dogma of cancer metabolism theory

January 09, 2019

Scientists at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have discovered that squamous cell skin cancers do not require increased glucose to power their development and growth, contrary to a long-held belief about cancer metabolism.

The findings could bring about a better understanding of many cancers' metabolic needs and lead to the development of more effective therapies for squamous cell skin cancer and other forms of epithelial cancer.

The research, led by senior authors Heather Christofk and Bill Lowry, https://www.nature.com/articles/s41467-018-07857-9">was published in the journal Nature Communications.

A fundamental doctrine of cancer metabolism theory is that cancer cells are glycolytic, meaning they consume more glucose and produce more lactate than normal cells. This metabolic shift, called aerobic glycolysis, or the Warburg effect, has been observed in thousands of experiments and inspired treatments that aim to stop tumor growth by preventing cancer cells from increasing their glucose consumption. To date, this treatment approach has not proven successful in clinical trials.

Considering these clinical limitations, Christofk and Lowry set out to examine if increased glucose consumption is truly indispensable to cancer formation and growth.

They decided to approach this problem using squamous cell skin cancer as a model, as they had made two key discoveries about the nature of this cancer in recent years.

In 2011, they determined that squamous cell skin cancer, which forms in the thin, flat cells found on the surface of the skin - can originate from hair follicle stem cells. Hair follicle stem cells produce hair throughout a person's lifetime and remain mostly inactive, but spring to action during a new hair cycle, which is when new hair growth occurs. In 2017, the pair found that hair follicle stem cells are glycolytic and ramp up their glucose consumption to quickly activate and produce hair follicles.

"These findings led us to question: Are squamous cell skin cancer cells glycolytic because they are cancer cells that altered their metabolism to fuel their rapid growth, or because the cells they originated from - hair follicle stem cells - were glycolytic?" said Lowry, a professor of molecular, cell and developmental biology.

To answer this question, the team studied the progression of squamous cell skin cancer in animal models whose hair follicle stem cells had been genetically modified to limit their glucose consumption. Specifically, they de-activated a gene called lactate dehydrogenase-a, which catalyzes the final step in a cell's process of converting glucose to lactate. Deactivating this gene prevented this final step from taking place, which in turn caused the cells to dramatically reduce their glucose consumption.

The change had no effect on cancer incidence or progression. When faced with insufficient glucose for their increased needs, the cancer cells in this model simply altered their metabolism to derive energy from the amino acid glutamine.

"These findings suggest that tumors are metabolically flexible and can use nutrients other than glucose to fuel growth," said Christofk, an associate professor of biological chemistry and molecular and medical pharmacology. "Understanding all of the nutrients cancers use for growth is critical to developing drugs that can successfully target cancer's metabolism."

The team double-checked their findings by conducting a converse experiment using hair follicle stem cells that had been genetically modified to increase glucose consumption. If their initial finding was incorrect, stimulating glucose consumption would make the tumors grow faster - it did not.

"The cells still formed cancer, but they didn't do so any faster and it wasn't any more serious," said Aimee Flores, a postdoctoral fellow in Lowry's lab and a first author of the study. "The behavior and progression of the disease was quite similar to the disease observed in the model with reduced glucose consumption."

As a next step, the team will conduct experiments to determine if reducing the consumption of both glucose and glutamine can stop the growth of squamous cell skin cancers.

"If limiting cancer's intake of both of these nutrients is shown to be effective, then that points to a path toward the clinic in the form of a combination therapy," said Lowry.

There is already some evidence that a combination therapy of this kind could treat squamous cell lung cancer. David Shackelford, an associate professor in the division of pulmonary and critical care medicine and a colleague of Christofk and Lowry's at the UCLA Jonsson Comprehensive Cancer Center, found that squamous cell lung cancers metabolize glutamine when unable to increase their glucose consumption.

Shackelford and his collaborators - including Christofk - also identified two drug candidates that, when used in combination, may stop the growth of squamous cell lung cancers by reducing the uptake of both of these nutrients.

Despite these encouraging findings, the road to bringing combination therapies for squamous cell cancers to humans is a long one, cautioned Lowry. "Every drug you add to a potential treatment carries its own risks and side effects, so identifying and testing combination therapies that will be both safe and effective in humans is a long and arduous process," he said.
-end-
This research was supported by the National Institutes of Health, an Impact Grant from the UCLA Jonsson Cancer Center Foundation and a Research Award from the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.

University of California - Los Angeles Health Sciences

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.